181 related articles for article (PubMed ID: 6354437)
41. In vitro cytotoxicity, cellular pharmacology, and DNA lesions induced by annamycin, an anthracycline derivative with high affinity for lipid membranes.
Ling YH; Priebe W; Yang LY; Burke TG; Pommier Y; Perez-Soler R
Cancer Res; 1993 Apr; 53(7):1583-9. PubMed ID: 8453627
[TBL] [Abstract][Full Text] [Related]
42. Intracellular adriamycin levels and cytotoxicity in adriamycin-sensitive and adriamycin-resistant P388 mouse leukemia cells.
Ganapathi R; Reiter W; Krishan A
J Natl Cancer Inst; 1982 Jun; 68(6):1027-32. PubMed ID: 6953267
[TBL] [Abstract][Full Text] [Related]
43. Biological effects of PEMF (pulsing electromagnetic field): an attempt to modify cell resistance to anticancer agents.
Pasquinelli P; Petrini M; Mattii L; Galimberti S; Saviozzi M; Malvaldi G
J Environ Pathol Toxicol Oncol; 1993; 12(4):193-7. PubMed ID: 8189374
[TBL] [Abstract][Full Text] [Related]
44. Cross resistance to esters of methotrexate in a doxorubicin-resistant subline of P388 murine leukemia.
Ramu A; Fridkin M; Steinherz R
Cancer Chemother Pharmacol; 1985; 15(1):31-4. PubMed ID: 4006047
[TBL] [Abstract][Full Text] [Related]
45. Promotion of daunorubicin uptake and toxicity by the calcium antagonist tiapamil and its analogs.
Kessel D; Wilberding C
Cancer Treat Rep; 1985 Jun; 69(6):673-6. PubMed ID: 4016770
[TBL] [Abstract][Full Text] [Related]
46. Modulation of doxorubicin resistance in P388/ADR cells by Ro44-5912, a tiapamil derivative.
De Jong G; Gelmon K; Bally M; Goldie J; Mayer L
Anticancer Res; 1995; 15(3):911-6. PubMed ID: 7645981
[TBL] [Abstract][Full Text] [Related]
47. Markedly reduced levels of anthracycline-induced DNA strand breaks in resistant P388 leukemia cells and isolated nuclei.
Capranico G; Riva A; Tinelli S; Dasdia T; Zunino F
Cancer Res; 1987 Jul; 47(14):3752-6. PubMed ID: 3474061
[TBL] [Abstract][Full Text] [Related]
48. Effects of Dex-Verapamil on Doxorubicin cytotoxicity in P388 murine leukemia cells.
Noviello E; Allievi E; Russo P; Parodi S
Anticancer Drug Des; 1997 Jun; 12(4):261-76. PubMed ID: 9199659
[TBL] [Abstract][Full Text] [Related]
49. Verapamil effect on the accumulation of doxorubicin in the leukemia P388 cells with induced antibiotic resistance.
Moroz LV; Donenko FV; Borovkova NB; Sitdikova SM
Arch Geschwulstforsch; 1990; 60(2):129-32. PubMed ID: 2339961
[TBL] [Abstract][Full Text] [Related]
50. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil.
Tsuruo T; Iida H; Tsukagoshi S; Sakurai Y
Cancer Res; 1981 May; 41(5):1967-72. PubMed ID: 7214365
[TBL] [Abstract][Full Text] [Related]
51. Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists.
Yang JM; Goldenberg S; Gottesman MM; Hait WN
Cancer Res; 1994 Feb; 54(3):730-7. PubMed ID: 7905786
[TBL] [Abstract][Full Text] [Related]
52. Restoration of sensitivity to oxazaphosphorines by inhibitors of aldehyde dehydrogenase activity in cultured oxazaphosphorine-resistant L1210 and cross-linking agent-resistant P388 cell lines.
Sladek NE; Landkamer GJ
Cancer Res; 1985 Apr; 45(4):1549-55. PubMed ID: 3978623
[TBL] [Abstract][Full Text] [Related]
53. Reversal of resistance to vincristine in P388 leukemia by various polycyclic clinical drugs, with a special emphasis on quinacrine.
Inaba M; Maruyama E
Cancer Res; 1988 Apr; 48(8):2064-7. PubMed ID: 3349478
[TBL] [Abstract][Full Text] [Related]
54. Calmodulin inhibitor trifluoperazine selectively enhances cytotoxic effects of strong vs weak DNA binding antitumor drugs in doxorubicin-resistant P388 mouse leukemia cells.
Ganapathi R; Grabowski D; Schmidt H; Seshadri R; Israel M
Biochem Biophys Res Commun; 1985 Sep; 131(2):912-9. PubMed ID: 2932108
[TBL] [Abstract][Full Text] [Related]
55. Techniques to reverse or circumvent drug-resistance in vitro.
Kuwano M; Nakagawa M; Shiraishi N; Yamaguchi T; Kikuchi J; Akiyama S
Prog Clin Biol Res; 1986; 223():163-71. PubMed ID: 3809198
[TBL] [Abstract][Full Text] [Related]
56. Potentiation of antitumor agents by calcium channel blockers with special reference to cross-resistance patterns.
Tsuruo T; Kawabata H; Nagumo N; Iida H; Kitatani Y; Tsukagoshi S; Sakurai Y
Cancer Chemother Pharmacol; 1985; 15(1):16-9. PubMed ID: 4006044
[TBL] [Abstract][Full Text] [Related]
57. [The cross resistance to cytostatics of leukemia P388 cells with induced resistance to doxorubicin].
Donenko FV; Sitdikova SM; Kabieva AO
Biull Eksp Biol Med; 1993 Sep; 116(9):309-11. PubMed ID: 8118011
[TBL] [Abstract][Full Text] [Related]
58. Characterization of four drug-resistant P388 sublines: resistance/sensitivity in vivo, resistance-and proliferation-markers, immunogenicity.
Fichtner I; Stein U; Hoffmann J; Winterfeld G; Pfeil D; Hentschel M
Anticancer Res; 1994; 14(5A):1995-2003. PubMed ID: 7847840
[TBL] [Abstract][Full Text] [Related]
59. Differential agglutination of P388 adriamycin-sensitive and P388 adriamycin-resistant leukemia cells.
Basrur VS; Chitnis MP; Menon RS
Oncology; 1983; 40(3):202-4. PubMed ID: 6843944
[TBL] [Abstract][Full Text] [Related]
60. Characterization of cellular lipids in doxorubicin-sensitive and -resistant P388 mouse leukemia cells.
Holleran WM; DeGregorio MW; Ganapathi R; Wilbur JR; Macher BA
Cancer Chemother Pharmacol; 1986; 17(1):11-5. PubMed ID: 3698172
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
